First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Nobuhiro HataMasahiro MizoguchiDaisuke KugaRyusuke HataeYojiro AkagiYuhei SangatsudaTakeo AmemiyaYuhei MichiwakiYutaka FujiokaKosuke TakigawaSatoshi O SuzukiTadamasa YoshitakeOsamu TogaoAkio HiwatashiKoji YoshimotoKoji IiharaPublished in: Journal of neuro-oncology (2020)
Our findings imply that optional first-line administration of BEV can overcome the impact of conventional risk factors and prolong survival complementary to TMZ. The patient subgroups benefitting from TMZ and BEV did not seem to overlap, and stratification based on risk factors, including MGMT methylation status, might be effective for selecting patients in whom BEV should be preferentially used as a first-line therapy.